Loading company
Chemomab Therapeutics Ltd.
CMMB · Nasdaq · ·
Next earnings: October 1, 2026
$1.610.0%Sep 29 close
- 1M
- -40.6%
- 6M
- +8.8%
- 1Y
- -38.8%
- 5Y
- -96.7%
CMMB · Nasdaq · ·
Next earnings: October 1, 2026
$1.610.0%Sep 29 close
Chemomab Therapeutics Ltd. is scheduled to report next on October 1, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toJun 30, 2023 | Change |
|---|---|---|---|
| Profit | -$2.1M | -$8M | +74.19% |
| Profit per share | -$1.02 | -$2.83 | +64.06% |
| Free Cash Flow | -$5.2M | -$5.3M | +1.42% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Chemomab Therapeutics Ltd. has no earnings call transcript available.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening immune-fibrotic diseases. Chemomab has reported positive results from five clinical trials of nebokitug, including the Phase 2 SPRING trial in patients with primary sclerosing cholangitis.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Chemomab Therapeutics Ltd. filed on August 19, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.